Exelixis Inc (EXEL) support and resistance · P/E 17, rev $628.7M
Exelixis Inc (EXEL) is a biotechnology company listed on US.
This page maps Exelixis Inc (EXEL) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported EXEL revenue for 2026-07-03 was $628.7M. Net income was $212.1M. Revenue was up 2.9% from 2026-04-03 to 2026-07-03. EXEL currently screens at market cap $12.69B and trailing P/E 16.7.
EXEL currently screens at market cap $12.69B and trailing P/E 16.7. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new EXEL 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the EXEL quote page for the session range and the stock page for the full model.
Not investment advice.